<p>Context Therapeutics（纳斯达克代码：CNTX - 获取免费报告）于周三发布了季度财报。该公司报告每股收益（EPS）为（$0.10），低于分析师一致预期的（$0.09），差距为（$0.01），据 Zacks 报道。</p>
<p>获取 <strong>Context Therapeutics</strong> 的提醒：</p>
<h2>Context Therapeutics 股价上涨 1.8%</h2>
<p>周三午盘交易中，CNTX 股价上涨 $0.02，达到 $1.13。该公司交易了 348,243 股，较其平均交易量 495,297 股有所减少。该股票的 50 日移动平均价为 $1.06，200 日移动平均价为 $0.85。Context Therapeutics 的一年最低价为 $0.49，一年最高价为 $2.32。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究公司对 CNTX 发布了报告。Guggenheim 于 9 月 18 日星期四开始覆盖 Context Therapeutics 的股票。他们对该股票设定了 “买入” 评级和 $5.00 的目标价。HC Wainwright 将 Context Therapeutics 的目标价从 $5.00 下调至 $4.00，并在 8 月 7 日的报告中对该股票设定了 “买入” 评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Context Therapeutics 的 “卖出（d-）” 评级。D. Boral Capital 在 10 月 16 日的报告中重新发布了 “买入” 评级，并对 Context Therapeutics 的股票设定了 $9.00 的目标价。最后，Cantor Fitzgerald 于 10 月 2 日星期四开始覆盖 Context Therapeutics 的股票。他们对该股票发布了 “增持” 评级。一位分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 $5.20。</p>
<p><strong>查看我们关于 CNTX 的最新研究报告</strong></p>
<h2>关于 Context Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Context Therapeutics Inc 是一家生物制药公司，开发用于治疗实体肿瘤的产品。其主要候选项目是 CTIM-76，一种抗 Claudin 6（CLDN6）x 抗 CD3 双特异性抗体，旨在将 T 细胞介导的裂解重定向到表达 CLDN6 的恶性细胞。该公司与 Integral Molecular, Inc 签订了合作和许可协议，开发用于癌症治疗的 CLDN6 双特异性单克隆抗体。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Context Therapeutics</li>
<li>交易暂停的解释</li>
<li>目前具有高增长潜力的 3 只现金丰富股票</li>
<li>什么是热门股票？热门股票的解释</li>
<li>为什么垂直航空股票在这次飞行测试后可能翻倍</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>亚马逊：突破确认——接下来可能会去哪里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Context Therapeutics 吗？</h2>
<p>在考虑投资 Context Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Context Therapeutics 并不在名单上。</p>
<p>虽然 Context Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CNTX

<p>Context Therapeutics（纳斯达克代码：CNTX）报告的季度每股收益为（$0.10），低于分析师预期的（$0.09），差距为$0.01。该股票上涨 1.8%，至$1.13，市场共识评级为 “适度买入”，平均目标价格为$5.20。分析师的评级各不相同，其中一位为强烈买入，七位为买入，一位为卖出。该公司专注于开发实体肿瘤的治疗方案，其主要候选药物为 CTIM-76，一种用于癌症治疗的双特异性抗体</p>

<p>Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01), Zacks reports.</p>
<div class="lb-trans"><p>Context Therapeutics（纳斯达克代码：CNTX - 获取免费报告）于周三发布了季度财报。该公司报告每股收益（EPS）为（$0.10），低于分析师一致预期的（$0.09），差距为（$0.01），据 Zacks 报道。</p>
</div><p>Get <strong>Context Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Context Therapeutics</strong> 的提醒：</p>
</div><h2>Context Therapeutics Trading Up 1.8%</h2>
<div class="lb-trans"><h2>Context Therapeutics 股价上涨 1.8%</h2>
</div><p>Shares of CNTX traded up $0.02 during midday trading on Wednesday, hitting $1.13. 348,243 shares of the company traded hands, compared to its average volume of 495,297. The stock has a 50-day moving average of $1.06 and a 200-day moving average of $0.85. Context Therapeutics has a one year low of $0.49 and a one year high of $2.32.</p>
<div class="lb-trans"><p>周三午盘交易中，CNTX 股价上涨 $0.02，达到 $1.13。该公司交易了 348,243 股，较其平均交易量 495,297 股有所减少。该股票的 50 日移动平均价为 $1.06，200 日移动平均价为 $0.85。Context Therapeutics 的一年最低价为 $0.49，一年最高价为 $2.32。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have issued reports on CNTX. Guggenheim began coverage on shares of Context Therapeutics in a report on Thursday, September 18th. They set a &#34;buy&#34; rating and a $5.00 price objective on the stock. HC Wainwright cut their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, August 7th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Context Therapeutics in a report on Wednesday, October 8th. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Thursday, October 16th. Finally, Cantor Fitzgerald initiated coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They issued an &#34;overweight&#34; rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $5.20.</p>
<div class="lb-trans"><p>多家研究公司对 CNTX 发布了报告。Guggenheim 于 9 月 18 日星期四开始覆盖 Context Therapeutics 的股票。他们对该股票设定了 “买入” 评级和 $5.00 的目标价。HC Wainwright 将 Context Therapeutics 的目标价从 $5.00 下调至 $4.00，并在 8 月 7 日的报告中对该股票设定了 “买入” 评级。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Context Therapeutics 的 “卖出（d-）” 评级。D. Boral Capital 在 10 月 16 日的报告中重新发布了 “买入” 评级，并对 Context Therapeutics 的股票设定了 $9.00 的目标价。最后，Cantor Fitzgerald 于 10 月 2 日星期四开始覆盖 Context Therapeutics 的股票。他们对该股票发布了 “增持” 评级。一位分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 $5.20。</p>
</div><p><strong>View Our Latest Research Report on CNTX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CNTX 的最新研究报告</strong></p>
</div><h2>About Context Therapeutics</h2>
<div class="lb-trans"><h2>关于 Context Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.</p>
<div class="lb-trans"><p>Context Therapeutics Inc 是一家生物制药公司，开发用于治疗实体肿瘤的产品。其主要候选项目是 CTIM-76，一种抗 Claudin 6（CLDN6）x 抗 CD3 双特异性抗体，旨在将 T 细胞介导的裂解重定向到表达 CLDN6 的恶性细胞。该公司与 Integral Molecular, Inc 签订了合作和许可协议，开发用于癌症治疗的 CLDN6 双特异性单克隆抗体。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Context Therapeutics</li>
<li>Trading Halts Explained</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Context Therapeutics</li>
<li>交易暂停的解释</li>
<li>目前具有高增长潜力的 3 只现金丰富股票</li>
<li>什么是热门股票？热门股票的解释</li>
<li>为什么垂直航空股票在这次飞行测试后可能翻倍</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>亚马逊：突破确认——接下来可能会去哪里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Context Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Context Therapeutics 吗？</h2>
</div><p>Before you consider Context Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Context Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Context Therapeutics 并不在名单上。</p>
</div><p>While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Context Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Context Therapeutics (NASDAQ:CNTX) 公布了财报结果